ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-OR013

Integrating Pathomic and Clinical Data Using Artificial Intelligence (AI) Models from Kidney Deceased Donors to Reduce Organ Discard and Improve Transplant Outcomes

Session Information

Category: Artificial Intelligence, Digital Health, and Data Science

  • 300 Artificial Intelligence, Digital Health, and Data Science

Authors

  • Rodrigues, Luis, Universidade de Coimbra, Coimbra, Coimbra District, Portugal
  • Paul, Anindya S., University of Florida, Gainesville, Florida, United States
  • Rubin, Jeremy, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Abdelazim, Haitham M, University of Florida, Gainesville, Florida, United States
  • Gupta, Akshita, University of Florida, Gainesville, Florida, United States
  • Border, Samuel, University of Florida, Gainesville, Florida, United States
  • Pardinhas, Clara, Universidade de Coimbra, Coimbra, Coimbra District, Portugal
  • Sousa, Vitor Manuel Leitão de, Universidade de Coimbra, Coimbra, Coimbra District, Portugal
  • Figueiredo, Arnaldo, Universidade de Coimbra, Coimbra, Coimbra District, Portugal
  • Zee, Jarcy, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Sarder, Pinaki, University of Florida, Gainesville, Florida, United States
Background

The limited availability of donor kidneys remains a major barrier to transplantation. Procurement biopsies help assess organ quality but are linked to high discard rates, raising concerns that viable kidneys may be excluded due to current evaluation limitations. We developed ComPRePS [https://compreps.wiki/home], a cloud-based AI/ML computational pathology platform for kidney biopsy analysis. This study aimed to build a model combining pathological and clinical data to better assess graft potential and reduce discard rates.

Methods

We analyzed 211 procurement core biopsies from 152 deceased donors: 139 kidneys from 110 donors were transplanted, while 72 from 42 donors were discarded based on biopsy findings. Samples were FFPE-processed, PAS-stained, and digitized at 40X. Donors were 64.5% male, mean age 62.3 years; KDPI averaged 69.5 (39.5% >85%). Using ComPRePS, we segmented glomeruli, tubules, arteries, arterioles, and lesions (e.g., IFTA, vascular fibrointimal sclerosis). From these, 306 pathomic features were extracted, quantifying size, texture, and morphology across eosinophilic, luminal, and nuclear subregions.

We computed a hybrid pathologist–AI lesion score (Remuzzi: RZAI) and tested regression models. Features were selected using Minimum Redundancy Maximum Relevance, with bootstrapping and five-fold cross-validation. Model performance was evaluated using mean squared error and C-statistics. Two random forest models were selected: one to predict 12-month eGFR and another for Delayed Graft Function (DGF). We then estimated potential discard reduction by identifying discarded kidneys using thresholds: eGFR ≥30 (CKD stage 3), RZAI ≤5 (on-call pathologist cutoff for usability), and low DGF risk (Youden’s index <0.49). Projected organ utilization gains were calculated.

Results

Applying these criteria, discard reduction ranged from 56.9% to 100%, with projected utilization gains from 5% to 44.6% (Table 1).

Conclusion

Computational pathology significantly improves graft prediction and supports better donor kidney utilization.

Funding

  • NIDDK Support

Digital Object Identifier (DOI)